Simfini-TUMOR
Long bone skeletal metastases are common in the US, with more than 280,000 new cases every year. Clinical dilemma: whether the metastatic tumor has weakened the bone sufficiently such that a pathological fracture is imminent. To answer that question, physicians rely primarily on Mirels’ Criterion which has been criticized by MDs regarding its ability to predict fractures. Simfini-TUMOR provides a reliable risk of fracture assessment to address this clinical dilemma. Hence, fewer unnecessary surgeries need be performed.